000136740 001__ 136740
000136740 005__ 20240229105056.0
000136740 0247_ $$2doi$$a10.1002/ijc.31335
000136740 0247_ $$2pmid$$apmid:29473162
000136740 0247_ $$2pmc$$apmc:PMC6019150
000136740 0247_ $$2ISSN$$a0020-7136
000136740 0247_ $$2ISSN$$a1097-0215
000136740 0247_ $$2altmetric$$aaltmetric:33622791
000136740 037__ $$aDKFZ-2018-01178
000136740 041__ $$aeng
000136740 082__ $$a610
000136740 1001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b0$$eFirst author$$udkfz
000136740 245__ $$aTumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
000136740 260__ $$aBognor Regis$$bWiley-Liss$$c2018
000136740 3367_ $$2DRIVER$$aarticle
000136740 3367_ $$2DataCite$$aOutput Types/Journal article
000136740 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536308470_14252
000136740 3367_ $$2BibTeX$$aARTICLE
000136740 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136740 3367_ $$00$$2EndNote$$aJournal Article
000136740 520__ $$aImmuno-proteomic screening has identified several tumor-associated autoantibodies (AAb) that may have diagnostic capacity for invasive epithelial ovarian cancer, with AAbs to P53 proteins and cancer-testis antigens (CTAGs) as prominent examples. However, the early detection potential of these AAbs has been insufficiently explored in prospective studies. We performed ELISA measurements of AAbs to CTAG1A, CTAG2, P53 and NUDT11 proteins, for 194 patients with ovarian cancer and 705 matched controls from the European EPIC cohort, using serum samples collected up to 36 months prior to diagnosis under usual care. CA125 was measured using electrochemo-luminiscence. Diagnostic discrimination statistics were calculated by strata of lead-time between blood collection and diagnosis. With lead times ≤6 months, ovarian cancer detection sensitivity at 0.98 specificity (SE98) varied from 0.19 [95% CI 0.08-0.40] for CTAG1A, CTAG2 and NUDT1 to 0.23 [0.10-0.44] for P53 (0.33 [0.11-0.68] for high-grade serous tumors). However, at longer lead-times, the ability of these AAb markers to distinguish future ovarian cancer cases from controls declined rapidly; at lead times >1 year, SE98 estimates were close to zero (all invasive cases, range: 0.01-0.11). Compared to CA125 alone, combined logistic regression scores of AAbs and CA125 did not improve detection sensitivity at equal level of specificity. The added value of these selected AAbs as markers for ovarian cancer beyond CA125 for early detection is therefore limited.
000136740 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000136740 588__ $$aDataset connected to CrossRef, PubMed,
000136740 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b1$$udkfz
000136740 7001_ $$0P:(DE-He78)6519c85d61a3def7974665471b8a4f74$$aHüsing, Anika$$b2$$udkfz
000136740 7001_ $$0P:(DE-He78)9c1a5b028ca0ab2ef3468a9266f81f63$$aBarrdahl, Myrto$$b3$$udkfz
000136740 7001_ $$aHopper, Marika$$b4
000136740 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron Scot$$b5$$udkfz
000136740 7001_ $$aTjønneland, Anne$$b6
000136740 7001_ $$aHansen, Louise$$b7
000136740 7001_ $$aOvervad, Kim$$b8
000136740 7001_ $$aFournier, Agnès$$b9
000136740 7001_ $$aBoutron-Ruault, Marie-Christine$$b10
000136740 7001_ $$aKvaskoff, Marina$$b11
000136740 7001_ $$aDossus, Laure$$b12
000136740 7001_ $$aJohansson, Mattias$$b13
000136740 7001_ $$aBoeing, Heiner$$b14
000136740 7001_ $$aTrichopoulou, Antonia$$b15
000136740 7001_ $$aBenetou, Vassiliki$$b16
000136740 7001_ $$00000-0003-1441-897X$$aLa Vecchia, Carlo$$b17
000136740 7001_ $$aSieri, Sabina$$b18
000136740 7001_ $$aMattiello, Amalia$$b19
000136740 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b20
000136740 7001_ $$aTumino, Rosario$$b21
000136740 7001_ $$00000-0003-0674-7757$$aMatullo, Giuseppe$$b22
000136740 7001_ $$aOnland-Moret, N Charlotte$$b23
000136740 7001_ $$aGram, Inger T$$b24
000136740 7001_ $$aWeiderpass, Elisabete$$b25
000136740 7001_ $$aSánchez, Maria-Jose$$b26
000136740 7001_ $$aNavarro Sanchez, Carmen$$b27
000136740 7001_ $$00000-0001-5256-0163$$aDuell, Eric J$$b28
000136740 7001_ $$aArdanaz, Eva$$b29
000136740 7001_ $$aLarranaga, Nerea$$b30
000136740 7001_ $$aLundin, Eva$$b31
000136740 7001_ $$aIdahl, Annika$$b32
000136740 7001_ $$aJirström, Karin$$b33
000136740 7001_ $$aNodin, Björn$$b34
000136740 7001_ $$aTravis, Ruth C$$b35
000136740 7001_ $$aRiboli, Elio$$b36
000136740 7001_ $$aMerritt, Melissa$$b37
000136740 7001_ $$aAune, Dagfinn$$b38
000136740 7001_ $$aTerry, Kathryn$$b39
000136740 7001_ $$aCramer, Daniel W$$b40
000136740 7001_ $$aAnderson, Karen S$$b41
000136740 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.31335$$gVol. 143, no. 3, p. 515 - 526$$n3$$p515 - 526$$tInternational journal of cancer$$v143$$x0020-7136$$y2018
000136740 909CO $$ooai:inrepo02.dkfz.de:136740$$pVDB
000136740 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136740 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136740 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6519c85d61a3def7974665471b8a4f74$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136740 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9c1a5b028ca0ab2ef3468a9266f81f63$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136740 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000136740 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000136740 9141_ $$y2018
000136740 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136740 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136740 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136740 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136740 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000136740 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136740 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136740 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136740 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136740 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136740 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136740 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000136740 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000136740 980__ $$ajournal
000136740 980__ $$aVDB
000136740 980__ $$aI:(DE-He78)C020-20160331
000136740 980__ $$aUNRESTRICTED